

# Jan Pruim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6378581/publications.pdf>

Version: 2024-02-01

34  
papers

2,429  
citations

471061

17  
h-index

454577

30  
g-index

35  
all docs

35  
docs citations

35  
times ranked

3010  
citing authors

#	ARTICLE	IF	CITATIONS
1	Application of artificial intelligence in nuclear medicine and molecular imaging; a review of current status and future perspectives for clinical translation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4452-4463.	3.3	29
2	Is $^{11}\text{C}$ Methionine PET an alternative to $^{18}\text{F}$ FDG-PET for identifying recurrent laryngeal cancer after radiotherapy?. <i>Clinical Otolaryngology</i> , 2019, 44, 124-130.	0.6	6
3	$^{99\text{m}}\text{Tc}$ -HDP bone scintigraphy and $^{18}\text{F}$ -sodiumfluoride PET/CT in primary staging of patients with prostate cancer. <i>World Journal of Urology</i> , 2018, 36, 27-34.	1.2	25
4	Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2404-2412.	3.3	21
5	$^{18}\text{F}$ -DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1797-1804.	2.8	50
6	Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition. <i>PLoS ONE</i> , 2016, 11, e0149955.	1.1	11
7	Impact of fasting on $^{18}\text{F}$ -fluorocholine gastrointestinal uptake and detection of lymph node metastases in patients with prostate cancer. <i>EJNMMI Research</i> , 2016, 6, 2.	1.1	3
8	An exploratory study of volumetric analysis for assessing tumor response with $^{18}\text{F}$ -FAZA PET/CT in patients with advanced non-small-cell lung cancer (NSCLC). <i>EJNMMI Research</i> , 2016, 6, 33.	1.1	11
9	Effectiveness of an $^{18}\text{F}$ -FDG-PET based strategy to optimize the diagnostic trajectory of suspected recurrent laryngeal carcinoma after radiotherapy: The RELAPS multicenter randomized trial. <i>Radiotherapy and Oncology</i> , 2016, 118, 251-256.	0.3	20
10	Clinical impact of $^{11}\text{C}$ -Choline PET/CT in selection and outcome of salvage cryoablation in patients with recurrent prostate cancer after radiotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 276-276.	0.8	0
11	Evaluation of elastix-based propagated align algorithm for VOI- and voxel-based analysis of longitudinal $^{18}\text{F}$ -FDG PET/CT data from patients with non-small cell lung cancer (NSCLC). <i>EJNMMI Research</i> , 2015, 5, 15.	1.1	7
12	Assessment of hypoxic subvolumes in laryngeal cancer with $^{18}\text{F}$ -fluoroazomycin-araboside ( $^{18}\text{F}$ -FAZA)-PET/CT scanning and immunohistochemistry. <i>Radiotherapy and Oncology</i> , 2015, 117, 106-112.	0.3	10
13	Dynamics of tumor hypoxia assessed by $^{18}\text{F}$ -FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: Possible implications for radiotherapy treatment planning strategies. <i>Radiotherapy and Oncology</i> , 2014, 113, 198-203.	0.3	66
14	Clinical validation of FDG-PET/CT in the radiation treatment planning for patients with oesophageal cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 188-192.	0.3	18
15	Head and Neck Tumor Hypoxia Imaging by $^{18}\text{F}$ -Fluoroazomycin-araboside ( $^{18}\text{F}$ -FAZA)-PET. <i>Clinical Nuclear Medicine</i> , 2014, 39, 44-48.	0.7	48
16	First Clinical Results of (d)- $^{18}\text{F}$ -Fluoromethyltyrosine (BAY 86-9596) PET/CT in Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1778-1785.	2.8	19
17	Prospective analysis of serial FLT-PET scanning to discriminate between true and pseudoprogression in glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2009-2009.	0.8	2
18	Total body metabolic tumor response in ALK-positive non-small cell lung cancer treated with crizotinib.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19062-e19062.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Alternative PET tracers in head and neck cancer. A review. European Archives of Oto-Rhino-Laryngology, 2013, 270, 2595-2601.	0.8	7
20	Oesophageal tumour progression between the diagnostic 18F-FDG-PET and the 18F-FDG-PET for radiotherapy treatment planning. Radiotherapy and Oncology, 2013, 106, 283-287.	0.3	20
21	11C-choline PET/CT in selection of patients for salvage cryoablation in recurrent prostate cancer.. Journal of Clinical Oncology, 2013, 31, 188-188.	0.8	0
22	Prognostic impact of hexokinase and glucose transporter expressions and clinicopathologic features related to F-18-FDG uptake in esophageal cancer.. Journal of Clinical Oncology, 2012, 30, 39-39.	0.8	0
23	FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 181-200.	3.3	1,147
24	A systematic review on the role of FDG-PET/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer. Radiotherapy and Oncology, 2010, 97, 165-171.	0.3	78
25	FDG-PET and detection of distant metastases and simultaneous tumors in head and neck squamous cell carcinoma: A comparison with chest radiography and chest CT. Oral Oncology, 2009, 45, 234-240.	0.8	58
26	Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer. Radiotherapy and Oncology, 2009, 93, 447-453.	0.3	64
27	The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2320-2333.	3.3	343
28	Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: A prospective multicenter trial. Radiotherapy and Oncology, 2008, 87, 221-229.	0.3	97
29	Blinded Mid-Treatment FDG-PET in Newly Diagnosed Aggressive Non-Hodgkin Lymphoma (NHL): First Results of a Prospective Multicenter Study.. Blood, 2006, 108, 2400-2400.	0.6	1
30	PTLD Visualization by FDG-PET: Improved Detection of Extranodal Localizations and Response Monitoring.. Blood, 2005, 106, 5389-5389.	0.6	0
31	Prediction of survival and therapy outcome with 11C-tyrosine PET in patients with laryngeal carcinoma. Journal of Nuclear Medicine, 2004, 45, 2052-7.	2.8	3
32	Carbon-11 tyrosine PET for visualization and protein synthesis rate assessment of laryngeal and hypopharyngeal carcinomas. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1182-1187.	3.3	13
33	Carbon-11 choline or FDG-PET for staging of oesophageal cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1845-1849.	3.3	44
34	Detection of unknown occult primary tumors using positron emission tomography. , 1998, 82, 1160-1166.		204